Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

AIM: The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion. METHODS: One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d....

Descripción completa

Detalles Bibliográficos
Autores principales: Ezekowitz, Michael D, Pollack, Charles V, Halperin, Jonathan L, England, Richard D, VanPelt Nguyen, Sandra, Spahr, Judith, Sudworth, Maria, Cater, Nilo B, Breazna, Andrei, Oldgren, Jonas, Kirchhof, Paulus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110194/
https://www.ncbi.nlm.nih.gov/pubmed/29659797
http://dx.doi.org/10.1093/eurheartj/ehy148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110194/
https://www.ncbi.nlm.nih.gov/pubmed/29659797
http://dx.doi.org/10.1093/eurheartj/ehy148

Ejemplares similares